LI-RADS 2018版钆塞酸增强MRI靶样表现:观察者间一致性与鉴别HCC与非HCC恶性肿瘤的诊断效能
该回顾性研究纳入100例高危患者,评估8名不同经验放射科医生对五种靶样表现的观察者间一致性及诊断非HCC恶性肿瘤的效能。现有至少一种靶样表现即LR-M的标准中位准确率62%、敏感度84%、特异度54%;要求至少三种或四种靶样表现时准确率最高(分别为79%和80%),一致性也有所改善。
要点
- 现有LR-M标准(至少一种靶样表现)敏感度84%但特异度仅54%,准确率62%。
- 要求至少三种靶样表现时中位准确率79%、敏感度68%、特异度82%;至少四种时准确率80%、敏感度54%、特异度88%。
- 靶样表现观察者间一致性差异大:周边廓清κ=0.20差,靶样移行期或肝胆期表现κ=0.33中等,靶样限制κ=0.43中等,边缘动脉期高强化κ=0.61较好。
核心结论
- 靶样表现及LR-M分类在经验较多与较少阅片者中均存在相当大的观察者间变异;要求多种靶样表现进行LR-M分类可改善观察者间一致性和对非HCC恶性肿瘤的诊断准确率。
研究设计与样本
- 回顾性研究,纳入100例HCC高危患者(76男24女,平均年龄58±9岁),均在肝肿瘤切除前30天内接受钆塞酸增强MRI;其中随机纳入25例非HCC恶性肿瘤(13例肝内胆管癌,12例混合型HCC-胆管癌),匹配75例HCC。来自7家机构的8名放射科医生(4名经验较多8-15年,4名经验较少1-5年)独立评估五种靶样表现及LI-RADS分类。
诊断标准与关键数值
- 五种靶样表现:周边廓清κ=0.20(差);靶样移行期或肝胆期表现κ=0.33(中等);延迟中心强化κ=0.37(中等);靶样限制κ=0.43(中等);边缘动脉期高强化κ=0.61(较好)。至少一种靶样表现κ=0.36(一般);至少两种、三种或四种靶样表现κ=0.43-0.51(中等)。现有LR-M标准(至少一种靶样表现)诊断非HCC恶性肿瘤中位准确率62%、敏感度84%、特异度54%;要求至少三种靶样表现时中位准确率79%、敏感度68%、特异度82%;要求至少四种时中位准确率80%、敏感度54%、特异度88%。
临床应用与阅片要点
- 作者结论提示,要求多种靶样表现进行LR-M分类可改善观察者间一致性和对非HCC恶性肿瘤的诊断准确率。
局限性
- 本文为回顾性研究。
- 样本量较小(共100例,其中非HCC恶性肿瘤25例)。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. In LI-RADS version 2018, observations showing at least one of five targetoid appearances in different sequences or postcontrast phases are categorized LR-M, indicating likely non-hepatocellular carcinoma (HCC) malignancy. OBJECTIVE. The purpose of this study was to evaluate interobserver agreement for LI-RADS targetoid appearances among a large number of radiologists of varying experience and the diagnostic performance of targetoid appearances for differentiating HCC from non-HCC malignancy. METHODS. This retrospective study included 100 patients (76 men, 24 women; mean age, 58 ± 9 [SD] years) at high risk of HCC who underwent gadoxetic acid-enhanced MRI within 30 days before hepatic tumor resection (25 randomly included patients with non-HCC malignancy [13, intrahepatic cholangiocarcinoma; 12, combined HCC-cholangiocarcinoma]; 75 matched patients with HCC). Eight radiologists (four more experienced [8-15 years]; four less experienced [1-5 years]) from seven institutions independently assessed observations for the five targetoid appearances and LI-RADS categorization. Interobserver agreement and diagnostic performance for non-HCC malignancy were evaluated. RESULTS. Interobserver agreement was poor for peripheral washout (κ = 0.20); moderate for targetoid transitional phase or hepatobiliary phase appearance (κ = 0.33), delayed central enhancement (κ = 0.37), and targetoid restriction (κ = 0.43); and substantial for rim arterial phase hyperenhancement (κ = 0.61). Agreement was fair for at least one targetoid appearance (κ = 0.36) and moderate for at least two, three, or four targetoid appearances (κ = 0.43-0.51). Agreement for individual targetoid appearances was not significantly different between more experienced and less experienced readers other than for targetoid restriction (κ = 0.63 vs 0.43; p = .001). Agreement for at least one targetoid appearance was fair among more experienced (κ = 0.29) and less experienced (κ = 0.37) reviewers. Agreement for at least two, three, or four targetoid appearances was moderate to substantial among more experienced reviewers (κ = 0.45-0.63) and moderate among less experienced reviewers (κ = 0.42-0.56). Existing LR-M criteria of at least one targetoid appearance had median accuracy for non-HCC malignancy of 62%, sensitivity of 84%, and specificity of 54%. For all reviewers, accuracy was highest when at least three (median accuracy, 79%; sensitivity, 68%; specificity, 82%) or four (median accuracy, 80%; sensitivity, 54%; specificity, 88%) targetoid appearances were required. CONCLUSION. Targetoid appearances and LR-M categorization exhibited considerable interobserver variation among both more and less experienced reviewers. CLINICAL IMPACT. Requiring multiple targetoid appearances for LR-M categorization improved interobserver agreement and diagnostic accuracy for non-HCC malignancy.
引用
- Min, Lee, Park, et al. LI-RADS Version 2018 Targetoid Appearances on Gadoxetic Acid-Enhanced MRI: Interobserver Agreement and Diagnostic Performance for the Differentiation of HCC and Non-HCC Malignancy. AJR Am J Roentgenol. 2022. PMID: 35319906. doi:10.2214/AJR.22.27380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。